Omega-3-acid ethyl esters

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Omega-3-acid ethyl esters
Accession Number
DB09539  (DB09540)
Type
Small Molecule
Groups
Approved, Investigational
Description

Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemiaLabel2. Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name LovazaLabel4.

Synonyms
  • Omega-3 fatty acid ethyl esters
  • Omega-3-acid ethyl esters
External IDs
K-85 / K85 / TAK-085
Active Moieties
NameKindUNIICASInChI Key
Omega-3 fatty acidsunknown71M78END5S329042-31-1Not applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LovazaCapsule, liquid filled1 g/1OralRebel Distributors2008-10-21Not applicableUs
LovazaCapsule, liquid filled900 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2008-10-212012-07-30Us
LovazaCapsule, liquid filled1 g/1OralPhysicians Total Care, Inc.2008-12-11Not applicableUs00173 0783 62 nlmimage10 4a192579
LovazaCapsule, liquid filled900 mg/1OralAtlantic Biologicals Corps.2008-10-21Not applicableUs17856 078320180907 15195 c4yd6l
LovazaCapsule, liquid filled900 mg/1OralGlaxoSmithKline LLC2016-05-19Not applicableUs
LovazaCapsule, liquid filled900 mg/1OralGlaxoSmithKline LLC2008-10-212019-10-31Us0173 078320180907 15195 1dafxz1
LovazaCapsule, liquid filled900 mg/1OralAtlantic Biologicals Corps.2016-05-19Not applicableUs
LovazaCapsule, liquid filled900 mg/1OralCardinal Health2008-10-212013-11-30Us55154 113420180913 8702 1uuutqm
OmacorCapsule, liquid filled1 g/1OralGlaxosmithkline Inc2007-03-012010-01-01Us
OmtrygCapsule900 mg/1OralTrygg Pharma, Inc.2016-07-01Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Omega-3-acid ethyl estersCapsule, liquid filled1 g/1OralAmerican Health Packaging2016-09-19Not applicableUs
Omega-3-acid Ethyl EstersCapsule, liquid filled900 mg/1OralAvera McKennan Hospital2015-04-282018-06-08Us69189 002720180907 15195 9etg13
Omega-3-Acid Ethyl EstersCapsule, liquid filled1 g/1OralAmneal Pharmaceuticals LLC2015-11-30Not applicableUs65162 03420180907 15195 9m0ms9
Omega-3-acid ethyl estersCapsule, liquid filled1 g/1Oralbryant ranch prepack2014-09-302017-06-30Us
Omega-3-acid ethyl estersCapsule, liquid filled900 mg/1OralPrasco Laboratories2016-03-312020-03-31Us
Omega-3-acid ethyl estersCapsule, liquid filled1 g/1OralA-S Medication Solutions2014-09-30Not applicableUs
Omega-3-Acid Ethyl EstersCapsule, liquid filled1 g/1OralAtlantic Biologicals Corps.2015-11-30Not applicableUs
Omega-3-Acid Ethyl EstersCapsule, liquid filled900 mg/1OralTeva Pharmaceuticals USA, Inc.2014-04-07Not applicableUs00093 5401 89 nlmimage10 8a3bc57e
Omega-3-acid ethyl estersCapsule, liquid filled1 g/1OralAvKARE, Inc.2015-05-07Not applicableUs
Omega-3-acid ethyl estersCapsule, liquid filled900 mg/1OralPrasco Laboratories2015-03-062019-05-31Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Omega-3 Rx CompleteOmega-3-acid ethyl esters (1 g/1) + Ascorbic acid (60 mg/1) + Biotin (.075 mg/1) + Calcium (210 mg/1) + Chromium nicotinate (.12 mg/1) + Copper (2 mg/1) + Cyanocobalamin (.018 mg/1) + Folic Acid (.4 mg/1) + Lycopene (.3 mg/1) + Magnesium (140 mg/1) + Magnesium oxide (140 mg/1) + Nicotinamide (18 mg/1) + Pantothenic acid (.016 mg/1) + Phylloquinone (.020 mg/1) + Riboflavin (1.7 mg/1) + Selenium (.11 mg/1) + Thiamine chloride (1.35 mg/1) + Vitamin A (3500 [iU]/1) + Vitamin D (700 [iU]/1) + Vitamin E (22.5 [iU]/1) + Zinc oxide (15 mg/1)KitOralTmig, Inc.2015-09-01Not applicableUs
Omega-3 Well PackOmega-3-acid ethyl esters (1 g/1) + Vitamin D (1000 [iU]/1)KitOralTmig, Inc.2015-09-01Not applicableUs
Sure Result O3D3 SystemOmega-3-acid ethyl esters (1 g/1g) + Vitamin D (1000 [iU]/1)KitInternational Brand Management, Llc2016-03-05Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Concept DHAOmega-3-acid ethyl esters (200 mg/1) + Ascorbic acid (25 mg/1) + Biotin (300 ug/1) + Cupric sulfate pentahydrate (2 mg/1) + Cyanocobalamin (12.5 ug/1) + Ferrous fumarate (53.5 mg/1) + Folic Acid (1 mg/1) + Iron (38 mg/1) + Magnesium sulfate (5 mg/1) + Niacin (1.8 mg/1) + Calcium pantothenate (5 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (3 mg/1) + Thiamine mononitrate (2 mg/1) + Zinc sulfate, unspecified form (10 mg/1)Capsule, liquid filledOralUs Pharmaceutical Corporation2009-06-24Not applicableUs
DivistaOmega-3-acid ethyl esters (300 mg/1) + Biotin (2 mg/1) + Chromium picolinate (1000 ug/1) + Cyanocobalamin (15 ug/1) + Folic Acid (1 mg/1) + Pyridoxine (25 mg/1)CapsuleOralUs Pharmaceutical Corporation2010-07-10Not applicableUs
Mi-Omega NFOmega-3-acid ethyl esters (500 mg/1) + Cyanocobalamin (500 ug/1) + Folic Acid (1 mg/1) + Pyridoxine hydrochloride (12.5 mg/1) + beta-Sitosterol (200 mg/1)CapsuleOralMayne Pharma2009-01-012016-05-31Us
Multinate DHAOmega-3-acid ethyl esters (430 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (3000 [iU]/1) + Calcium Carbonate (200 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Doconexent (295 mg/1) + Folic Acid (1 mg/1) + Iron (29 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Vitamin E (30 mg/1) + Zinc oxide (25 mg/1)KitRiver's Edge Pharmaceuticals, LLC2009-09-012011-04-20Us
Multinate DHAOmega-3-acid ethyl esters (400 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (3000 [iU]/1) + Calcium Carbonate (200 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Doconexent (275 mg/1) + Folic Acid (1 mg/1) + Iron (29 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Vitamin E (30 mg/1) + Zinc oxide (25 mg/1)KitRiver's Edge Pharmaceuticals, LLC2009-09-012012-11-30Us
Multinate DHA ExtraOmega-3-acid ethyl esters (430 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (3000 [iU]/1) + Calcium Carbonate (200 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Doconexent (295 mg/1) + Folic Acid (1 mg/1) + Iron (29 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Vitamin E (3 mg/1) + Zinc oxide (25 mg/1)KitRiver's Edge Pharmaceuticals, LLC2009-09-012012-03-31Us
Multinate DHA ExtraOmega-3-acid ethyl esters (400 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (3000 [iU]/1) + Calcium Carbonate (200 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Doconexent (275 mg/1) + Folic Acid (1 mg/1) + Iron (29 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Vitamin E (3 mg/1) + Zinc oxide (25 mg/1)KitRiver's Edge Pharmaceuticals, LLC2009-09-012011-04-20Us
RenateOmega-3-acid ethyl esters (430 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (3000 [iU]/1) + Calcium Carbonate (200 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Doconexent (295 mg/1) + Folic Acid (1 mg/1) + Iron (29 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Vitamin E (3 mg/1) + Zinc oxide (25 mg/1)TabletOralRiver's Edge Pharmaceuticals, LLC2009-01-022010-12-31Us
RenateOmega-3-acid ethyl esters (430 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (3000 [iU]/1) + Calcium Carbonate (200 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Doconexent (295 mg/1) + Folic Acid (1 mg/1) + Iron (29 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Vitamin E (3 mg/1) + Zinc oxide (25 mg/1)TabletOralRiver's Edge Pharmaceuticals, LLC2009-01-022011-08-31Us
RenateOmega-3-acid ethyl esters (400 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (3000 [iU]/1) + Calcium Carbonate (200 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + Doconexent (275 mg/1) + Folic Acid (1 mg/1) + Iron (29 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Vitamin E (3 mg/1) + Zinc oxide (25 mg/1)TabletOralRiver's Edge Pharmaceuticals, LLC2009-01-022010-09-30Us
Categories
UNII
D87YGH4Z0Q
CAS number
308081-97-2

Pharmacology

Indication

Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG)Label2.

Associated Conditions
Pharmacodynamics

Omega-3-acid ethyl esters reduce triglyceride production, increase fatty acid metabolism, inhibit the release of fatty acids, increase triglyceride clearance, and decrease production of very low density lipoprotein cholesterol(VLDL-C)2.

Mechanism of action

Omega-3-acid ethyl esters reduce triglyceride production by the liver but this mechanism is not well understood2. Omega-3-acid ethyl esters inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, reducing triglyceride synthesis and increasing paroxysmal beta-oxidation, which increases fatty aside metabolism2. Omega-3-acid ethyl esters also inhibit the release of fatty acids by competing for enzymes involved in the synthesis of triglycerides, increase triglyceride clearance by increasing the activity of lipoprotein lipase, and decrease production of VLDL-C2.

TargetActionsOrganism
USterol regulatory element-binding protein 1
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Omega-3-acid ethyl esters are rapidly hydrolysed to free fatty acids in the intestinal lumen which then become incorporated into phospholipids, cholesterol, and triglycerides so determination of bioavailability by serum concentration is not possible5,3.

Volume of distribution

82 ± 56L1

Protein binding

Because omega-3-acid ethyl esters are rapidly hydrolysed and incorporated into other processes and structures, protein binding data is scarceLabel5. However, most of EPA is bound to plasma protein6.

Metabolism

Omega-3-acid ethyl esters are hydrolysed to free fatty acids in the intestinal lumen by pancreatic lipase3. Once in enterocytes, the free fatty acids are packaged in chylomicrons which are released from cells into the circulation3. Fatty acids then enter the liver where they can be incorporated into liver stores, incorporated into lipoprotein phospholipids, or oxidised for energy5.

Route of elimination

Includes oxidative catabolism to carbon dioxide and water

Half life

79 hours ± 47 hours1.

Clearance

757 mL/h ± 283mL/h1.

Toxicity

In rats, omega-3-acid ethyl esters are not mutagenic or clastogenic and do not lead to impairment of fertilityLabel.

Safety in human pregnancy have not been performed, however an embryocidal effect was seen in rats force fed 7 times the maximum recommended human doseLabel. The risk and benefit of treatment during pregnancy should be weighed before deciding on treatmentLabel.

Animal studies in lactating rats have shown excretion of omega-3-acid ethyl esters at concentrations 6 to 14 times higher than in the serum of the mother, however the effects of this excretion on a mother or child have not been establishedLabel.

Safety and effectiveness in pediatric patients has not been establishedLabel.

There appear to be no differences in the safety and efficacy in patients above or below 60 years of age based on limited dataLabel.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with 4-hydroxycoumarin.
AbciximabThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Abciximab.
AcenocoumarolThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Acenocoumarol.
Acetylsalicylic acidThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Acetylsalicylic acid.
AlteplaseThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Alteplase.
AmediplaseThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Amediplase.
AnagrelideThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Anagrelide.
AncrodThe risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ancrod.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Braeckman RA, Stirtan WG, Soni PN: Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects. Clin Pharmacol Drug Dev. 2014 Mar;3(2):101-108. Epub 2013 Oct 22. [PubMed:26097787]
  2. Koski R: Omega-3-acid Ethyl Esters (Lovaza) For Severe Hypertriglyceridemia Pharmacy and Therapeutics. 2008 May;33(5):271-303.
  3. Davidson MH: Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013 Dec;24(6):467-74. doi: 10.1097/MOL.0000000000000019. [PubMed:24184945]
  4. Omega-3-acid ethyl esters 90 (K85EE) [Link]
  5. Australian Public Assessment Report for Omega-3-acid ethyl esters 90 [Link]
  6. FDA reports [Link]
External Links
PubChem Substance
347910460
Wikipedia
Omega-3_acid_ethyl_esters
FDA label
Download (177 KB)
MSDS
Download (176 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingSupportive CareCancer, Breast1
0CompletedTreatmentHealthy Volunteers1
0Not Yet RecruitingTreatmentCancer, Breast1
1CompletedTreatmentHypertriglyceridemias1
1CompletedTreatmentSevere Hypertriglyceridemia1
1RecruitingOtherHyperlipidemia, Hypertriglyceridemia1
1TerminatedTreatmentFatty Liver / Non-Alcoholic Fatty Liver Disease (NAFLD)1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2CompletedTreatmentHypertriglyceridemias1
1, 2CompletedTreatmentIncreased Drug Resistance1
1, 2Not Yet RecruitingTreatmentColorectal Cancers1
1, 2Not Yet RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1, 2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Not Yet RecruitingTreatmentMelanoma1
1, 2Not Yet RecruitingTreatmentNeuroendocrine Carcinoma of the Skin1
1, 2Not Yet RecruitingTreatmentNon Hodgkin Lymphoma (NHL)1
1, 2Not Yet RecruitingTreatmentTransitional Cell Carcinoma1
1, 2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentMyocardial Infarction1
1, 2WithdrawnTreatmentLiver Diseases / Short Bowel Syndrome (SBS)1
2Active Not RecruitingTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
2CompletedNot AvailableHeart Diseases / Human Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionCancer, Breast2
2CompletedPreventionColorectal Adenomatous Polyps1
2CompletedTreatmentBleeding / Cardiovascular Disease (CVD)1
2CompletedTreatmentExocrine Pancreatic Insufficiency / Type 2 Diabetes Mellitus1
2CompletedTreatmentMuscle Damage / Muscle Inflammation1
2CompletedTreatmentNon Familial Chylocmicronemia Syndrome (Non-FCS)1
2CompletedTreatmentSevere Hypertriglyceridemia1
2Not Yet RecruitingTreatmentColorectal Cancers / Lynch Syndrome1
2RecruitingDiagnosticTbi1
2RecruitingPreventionChronic Lung Diseases / Lung Cancer, Protection Against1
2TerminatedTreatmentHepatic Steatosis / Nonalcoholic Steatohepatitis (NASH)1
2TerminatedTreatmentHypertriglyceridemias1
2Unknown StatusSupportive CareCombat Disorders / Depression / Moods Disorders / Stress Disorders1
2WithdrawnTreatmentDepression1
2, 3CompletedTreatmentHypertriglyceridemias1
3CompletedPreventionIgA Nephropathy1
3CompletedPreventionNonvalvular Atrial Fibrillation1
3CompletedSupportive CarePeripheral Arterial Disease (PAD)1
3CompletedTreatmentDeath, Sudden,Cardiac / Myocardial Infarction1
3CompletedTreatmentHypertriglyceridemias5
3CompletedTreatmentInsulin Resistance1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3TerminatedPreventionCardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Endocrine System Diseases / Glucose Metabolism Disorders / Heart Diseases / High Blood Pressure (Hypertension) / Metabolic Diseases / Vascular Diseases1
3TerminatedTreatmentHeart Failure1
4Active Not RecruitingPreventionDiabetes Mellitus (DM)1
4CompletedNot AvailableMixed hypercholesterolemia1
4CompletedOtherBioavailability1
4CompletedOtherHyperlipidemias2
4CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Dyslipidemias / Human Immunodeficiency Virus (HIV) Infections / Hypertriglyceridemias1
4CompletedTreatmentAtherosclerosis / Type 2 Diabetes Mellitus1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentBipolar Disorder (BD) / High Cholesterol / High Triglycerides / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentCardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentDeficiency, Vitamin D / Hemodialysis Patients / Vitamin D Insufficiency1
4CompletedTreatmentDiabetic Neuropathies / Hypertriglyceridemias1
4CompletedTreatmentHigh Triglyceride Level / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Ischaemic Heart Diseases1
4CompletedTreatmentHypertriglyceridemias / Metabolic Syndromes1
4CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
4TerminatedTreatmentHyper-Triglyceridemia1
4Unknown StatusTreatmentBorderline Personality Disorder (BPD)1
4Unknown StatusTreatmentDyslipidemia (Fredrickson Type Ⅱa)1
4Unknown StatusTreatmentHigh Cholesterol / Hypertriglyceridemias / Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentHypertriglyceridemias1
4Unknown StatusTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
4Unknown StatusTreatmentNonvalvular Atrial Fibrillation1
4Unknown StatusTreatmentMixed hypercholesterolemia1
4WithdrawnTreatmentHypertriglyceridemias1
Not AvailableActive Not RecruitingNot AvailableHyperlipidemias1
Not AvailableActive Not RecruitingNot AvailableHistory of myocardial infarction / Hypertriglyceridemias1
Not AvailableCompletedNot AvailableHyperlipidemias1
Not AvailableCompletedBasic ScienceCardiovascular Disease (CVD)1
Not AvailableCompletedBasic ScienceHypertriglyceridemias1
Not AvailableCompletedBasic ScienceInflammatory Responses1
Not AvailableCompletedBasic ScienceInsulin Resistance / Metabolic Syndromes1
Not AvailableCompletedTreatmentCancer Cachexia1
Not AvailableCompletedTreatmentCoronary Artery Disease1
Not AvailableCompletedTreatmentDepression1
Not AvailableCompletedTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedTreatmentHypertriglyceridemias1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableNo Longer AvailableNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableTerminatedPreventionThoracic Pain1
Not AvailableTerminatedTreatmentCardiovascular Disease (CVD)1
Not AvailableUnknown StatusNot AvailableCoronary Artery Disease1
Not AvailableUnknown StatusHealth Services ResearchAttention-Deficit/Hyperactivity Disorder1
Not AvailableUnknown StatusTreatmentParenteral Nutrition Associated Liver Disease (PNALD)1
Not AvailableWithdrawnTreatmentPeripheral Artery Disease (PAD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Capsule, liquid filledOral
CapsuleOral
Capsule, liquid filledOral900 mg/1
Kit
Capsule, liquid filledOral1 g/1
KitOral
CapsuleOral1 g/1g
CapsuleOral900 mg/1
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)<20[MSDS]
boiling point (°C)>400[MSDS]
water solubilityNot Soluble[MSDS]
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function
Transcriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the fatty acid and to a lesser degree the cholesterol synthesis pathway (By sim...
Gene Name
SREBF1
Uniprot ID
P36956
Uniprot Name
Sterol regulatory element-binding protein 1
Molecular Weight
121673.6 Da
References
  1. Davidson MH: Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013 Dec;24(6):467-74. doi: 10.1097/MOL.0000000000000019. [PubMed:24184945]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sterol o-acyltransferase activity
Specific Function
Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol. Plays a role in lipoprotein assembly and dietary cholesterol absorption. In addition ...
Gene Name
SOAT1
Uniprot ID
P35610
Uniprot Name
Sterol O-acyltransferase 1
Molecular Weight
64733.975 Da

Drug created on November 30, 2015 12:10 / Updated on May 01, 2019 10:55